Mylan Undaunted By Other Duragesic Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
Fentanyl patch competitors have yet to deliver the product dependably, says Mylan CEO.
You may also be interested in...
FDA “First Generics” Policy Not Enough, Mylan CEO Says
Agency's ANDA review needs a top-to-bottom policy overhaul to end approval delays, Coury says.
FDA “First Generics” Policy Not Enough, Mylan CEO Says
Agency's ANDA review needs a top-to-bottom policy overhaul to end approval delays, Coury says.
Ditropan XL Generic Ready For Launch Pending FDA Approval, J&J Citizen Petition
Final appellate court ruling triggers an “exclusive supply agreement” between J&J and Mylan.